Vera Therapeutics stock: Leerink keeps a USD 34.00 target for Vera Therapeutics stock

Published on 10/28/2026 at 06:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Leerink kept a Hold rating and USD 34.00 target on October 27, 2026. For Vera Therapeutics stock, second-quarter GAAP loss was USD 109.5 million.

Trial data and reporting date

Leerink Partners kept a Hold rating and a USD 34.00 target on October 27, 2026.
ORIGIN 3 reported serious adverse events in 7 percent of patients receiving TRUTAKNA versus 15 percent with placebo on October 22, 2026.
Vera Therapeutics will discuss third-quarter 2026 results on November 5, 2026.

VERA, US92337R1014, Illustration mit AI erstellt.

Vera Therapeutics (ISIN US92337R1014) faces a USD 34.00 price target from Leerink Partners after the analyst firm maintained a Hold rating on October 27, 2026. The company also reported positive final ORIGIN 3 data for TRUTAKNA in IgA nephropathy on October 22.

Leerink keeps target at USD 34.00

According to Business Insider, Leerink Partners maintained its Hold rating and set a USD 34.00 target. The same report noted that Vera's second-quarter 2026 GAAP net loss was USD 109.47 million, compared with USD 76.53 million in the prior-year quarter.

What did ORIGIN 3 show?

Vera's final analysis found statistically significant results across all prespecified endpoints, including proteinuria reduction at 36 weeks. The company said serious adverse events occurred in 7 percent of patients receiving TRUTAKNA, versus 15 percent for placebo, according to its Vera Therapeutics release dated October 22, 2026. Management plans to submit a supplemental biologics license application to the U.S. Food and Drug Administration in the fourth quarter of 2026.

Three dated milestones

On October 12, 2026, Leerink initiated coverage with a USD 34.00 target, as reported by Marketscreener. On October 20, Vera scheduled its third-quarter results webcast for 4:30 p.m. ET on November 5, 2026, according to the company release. On October 27, Leerink maintained the USD 34.00 target and Hold rating.

Upcoming reporting date

Vera Therapeutics scheduled its third-quarter 2026 financial results webcast for November 5, 2026. The event will also cover business updates, giving investors a defined date for the next operating update.

Commercial stage and clinical risk

Vera Therapeutics describes itself as a commercial-stage biotechnology company focused on autoimmune disease and kidney disorders. The company is based in Brisbane, California, and its lead product is TRUTAKNA, which targets IgA nephropathy. The October 22 release also cautioned that accelerated approval remains subject to confirmation of clinical benefit.